Cargando…

Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients

OBJECTIVE: Urinary liver-type fatty acid–binding protein (L-FABP) is a promising indicator of tubular but not glomerular damage. The aim of this study was to evaluate the clinical usefulness of urinary L-FABP as a prognostic biomarker in impaired diabetic nephropathy in type 2 diabetes. RESEARCH DES...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamijo-Ikemori, Atsuko, Sugaya, Takeshi, Yasuda, Takashi, Kawata, Takehiro, Ota, Akio, Tatsunami, Shinobu, Kaise, Ruriko, Ishimitsu, Toshihiko, Tanaka, Yasushi, Kimura, Kenjiro
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041209/
https://www.ncbi.nlm.nih.gov/pubmed/21273494
http://dx.doi.org/10.2337/dc10-1392
_version_ 1782198420390281216
author Kamijo-Ikemori, Atsuko
Sugaya, Takeshi
Yasuda, Takashi
Kawata, Takehiro
Ota, Akio
Tatsunami, Shinobu
Kaise, Ruriko
Ishimitsu, Toshihiko
Tanaka, Yasushi
Kimura, Kenjiro
author_facet Kamijo-Ikemori, Atsuko
Sugaya, Takeshi
Yasuda, Takashi
Kawata, Takehiro
Ota, Akio
Tatsunami, Shinobu
Kaise, Ruriko
Ishimitsu, Toshihiko
Tanaka, Yasushi
Kimura, Kenjiro
author_sort Kamijo-Ikemori, Atsuko
collection PubMed
description OBJECTIVE: Urinary liver-type fatty acid–binding protein (L-FABP) is a promising indicator of tubular but not glomerular damage. The aim of this study was to evaluate the clinical usefulness of urinary L-FABP as a prognostic biomarker in impaired diabetic nephropathy in type 2 diabetes. RESEARCH DESIGN AND METHODS: This investigation involved a cross-sectional and longitudinal analysis of the relationship between urinary L-FABP levels and progressive nephropathy. Urinary L-FABP was measured with enzyme-linked immunosorbent assay. In the cross-sectional analysis, the association of urinary L-FABP, with the severity of diabetic nephropathy, was investigated in 140 patients with type 2 diabetes and in 412 healthy control subjects. Of the patients in the former study, 104 have been followed for 4 years. The progression of diabetic nephropathy was defined as progressive albuminuria, end-stage renal disease, or induction of hemodialysis. RESULTS: Urinary L-FABP levels were progressively increased in subjects with normo-, micro-, or macroalbuminuria and further increased in patients with end-stage renal disease. In the longitudinal analysis, high urinary L-FABP levels were associated with the increase in albuminuria, progression to end-stage renal disease, or induction of hemodialysis. This was particularly demonstrated in the subgroup of patients without renal dysfunction (n = 59), where high urinary L-FABP levels were associated with the progression of diabetic nephropathy. CONCLUSIONS: Urinary L-FABP accurately reflected the severity of diabetic nephropathy in type 2 diabetes, and its level was high in the patients with normoalbuminuria. Moreover, higher urinary L-FABP was a risk factor for progression of diabetic nephropathy.
format Text
id pubmed-3041209
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-30412092012-03-01 Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients Kamijo-Ikemori, Atsuko Sugaya, Takeshi Yasuda, Takashi Kawata, Takehiro Ota, Akio Tatsunami, Shinobu Kaise, Ruriko Ishimitsu, Toshihiko Tanaka, Yasushi Kimura, Kenjiro Diabetes Care Original Research OBJECTIVE: Urinary liver-type fatty acid–binding protein (L-FABP) is a promising indicator of tubular but not glomerular damage. The aim of this study was to evaluate the clinical usefulness of urinary L-FABP as a prognostic biomarker in impaired diabetic nephropathy in type 2 diabetes. RESEARCH DESIGN AND METHODS: This investigation involved a cross-sectional and longitudinal analysis of the relationship between urinary L-FABP levels and progressive nephropathy. Urinary L-FABP was measured with enzyme-linked immunosorbent assay. In the cross-sectional analysis, the association of urinary L-FABP, with the severity of diabetic nephropathy, was investigated in 140 patients with type 2 diabetes and in 412 healthy control subjects. Of the patients in the former study, 104 have been followed for 4 years. The progression of diabetic nephropathy was defined as progressive albuminuria, end-stage renal disease, or induction of hemodialysis. RESULTS: Urinary L-FABP levels were progressively increased in subjects with normo-, micro-, or macroalbuminuria and further increased in patients with end-stage renal disease. In the longitudinal analysis, high urinary L-FABP levels were associated with the increase in albuminuria, progression to end-stage renal disease, or induction of hemodialysis. This was particularly demonstrated in the subgroup of patients without renal dysfunction (n = 59), where high urinary L-FABP levels were associated with the progression of diabetic nephropathy. CONCLUSIONS: Urinary L-FABP accurately reflected the severity of diabetic nephropathy in type 2 diabetes, and its level was high in the patients with normoalbuminuria. Moreover, higher urinary L-FABP was a risk factor for progression of diabetic nephropathy. American Diabetes Association 2011-03 2011-02-17 /pmc/articles/PMC3041209/ /pubmed/21273494 http://dx.doi.org/10.2337/dc10-1392 Text en © 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
Kamijo-Ikemori, Atsuko
Sugaya, Takeshi
Yasuda, Takashi
Kawata, Takehiro
Ota, Akio
Tatsunami, Shinobu
Kaise, Ruriko
Ishimitsu, Toshihiko
Tanaka, Yasushi
Kimura, Kenjiro
Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients
title Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients
title_full Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients
title_fullStr Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients
title_full_unstemmed Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients
title_short Clinical Significance of Urinary Liver-Type Fatty Acid–Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patients
title_sort clinical significance of urinary liver-type fatty acid–binding protein in diabetic nephropathy of type 2 diabetic patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041209/
https://www.ncbi.nlm.nih.gov/pubmed/21273494
http://dx.doi.org/10.2337/dc10-1392
work_keys_str_mv AT kamijoikemoriatsuko clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT sugayatakeshi clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT yasudatakashi clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT kawatatakehiro clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT otaakio clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT tatsunamishinobu clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT kaiseruriko clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT ishimitsutoshihiko clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT tanakayasushi clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients
AT kimurakenjiro clinicalsignificanceofurinarylivertypefattyacidbindingproteinindiabeticnephropathyoftype2diabeticpatients